EFFICACY, SAFETY, AND TOLERABILITY OF CONTINUED LPCN 1144 TREATMENT IN NONALCOHOLIC STEATOHEPATITIS SUBJECTS WITH FIBROSIS IN AN OPEN LABEL EXTENSION STUDY Benjamin J Bruno1,. | October 27, 2022
SALT LAKE CITY, Dec. 22, 2021 /PRNewswire/ Lipocine Inc. , a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the first patient has. | December 22, 2021
LIPOCINE ANNOUNCES patient dosed in its Phase 2 Study with LPCN 1148 for management of liver cirrhosis SALT LAKE CITY, December 22, 2021 - Lipocine Inc. , a clinical-stage. | December 22, 2021